metricas
covid
Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An u...
Información de la revista
Vol. 29. Núm. 3.
(mayo - junio 2024)
Compartir
Compartir
Descargar PDF
Más opciones de artículo
Visitas
955
Vol. 29. Núm. 3.
(mayo - junio 2024)
Original article
Acceso a texto completo
Lean non-alcoholic fatty liver disease and the risk of all-cause mortality: An updated meta-analysis
Visitas
955
Wasit Wongtrakula,b, Natthinee Charatcharoenwitthayac, Phunchai Charatcharoenwitthayaa,
Autor para correspondencia
phunchai.cha@mahidol.ac.th

Corresponding author.
a Division of Gastroenterology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
b Department of Research and Development, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
c Division of Endocrinology and Metabolism. Department of Medicine, Faculty of Medicine Thammasat University, Pathumthani, Thailand
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (4)
Mostrar másMostrar menos
Tablas (3)
Table 1. Characteristics of cohort studies assessing overall mortality between lean and non-lean NAFLD populations included in the review.
Table 2. Subgroup analyses for associations between lean NAFLD and risk of all-cause mortality.
Table 3. Sensitivity analyses for the association between lean NAFLD and risk of all-cause mortality.
Mostrar másMostrar menos
Material adicional (3)
Abstract
Introduction and Objectives

Cohort studies reported controversial results regarding the long-term prognosis of patients with lean non-alcoholic fatty liver disease (NAFLD) compared to non-lean NAFLD patients. This updated meta-analysis aimed to estimate the magnitude of the association between lean body mass index and all-cause mortality risk in NAFLD patients.

Materials and Methods

We systematically searched the EMBASE and MEDLINE databases from inception to March 2023 to identify observational studies that reported hazard ratio (HR) for all-cause mortality of patients with lean NAFLD versus those with non-lean, overweight, or obese NAFLD. Multivariable-adjusted hazard ratios (HRs) for all-cause mortality were pooled using a random effects model.

Results

Fourteen studies with 94,181 NAFLD patients (11.3 % with lean NAFLD) and 7,443 fatal events over a median follow-up of 8.4 years (IQR, 6.6–17.4 years) were included. Patients with lean NAFLD had a higher risk of all-cause mortality than those with non-lean NAFLD (random-effects HR 1.61, 95 % CI 1.37–1.89; I2=77 %). The magnitude of this risk remained unchanged even after stratified analysis by measures of NAFLD diagnosis, study country, cohort setting, length of follow-up, adjustment with fibrosis stage/cirrhosis, and the Newcastle-Ottawa Scale. The risk was independent of age, sex, and cardiometabolic risk factors. Sensitivity analyses did not alter these findings. The funnel plot and Egger's test revealed no significant publication bias.

Conclusions

This meta-analysis revealed that lean NAFLD is associated with an approximately 1.6-fold increased mortality risk. Further studies are needed to unravel the existing but complex link between lean NAFLD and an increased risk of death.

Keywords:
Nonalcoholic fatty liver disease
Lean
Overweight
Obesity
Mortality
Meta-analysis
Abbreviations:
BMI
CI
CVD
HCC
HR
LAP
NA
NAFLD
NOS
Ob
Ow
RR
Texto completo
1Introduction

Non-alcoholic fatty liver disease (NAFLD) is a potentially severe liver disease that affects about one-quarter of the adult population worldwide [1,2]. NAFLD can progress from simple steatosis to non-alcoholic steatohepatitis, cirrhosis, liver decompensation, and hepatocellular carcinoma (HCC) [3]. Patients with NAFLD have been shown to have a higher risk of death from any cause than those without the disease [4,5]. Although obesity is a major contributing factor for NAFLD, approximately 20 % of NAFLD patients are lean [6]. NAFLD with normal weight (body mass index [BMI] <23 kg/m2 in Asians and <25 kg/m2 in people of other ethnicities), considered to be lean NAFLD, is thought to be more benign than NAFLD with higher BMI. Since individuals with lean NAFLD usually present with more favorable metabolic and histologic profiles, it is commonly believed that this lean group will follow a relatively benign clinical course than their overweight or obese counterparts [7,8]. However, an international cohort study by Dela Cruz et al. first reported increased mortality for patients with lean NAFLD compared with those with higher BMI [9]. Later, several studies on the mortality risk of lean NAFLD have discovered controversial results [10–17].

The impact of adiposity measures on the long-term prognosis of patients with NAFLD is currently a topic of intense scientific debate. In 2022, the first meta-analysis investigating the association between lean NAFLD and mortality risk was published. It included ten observational studies and concluded that the risk of all-cause mortality in lean NAFLD patients is comparable with that in patients with non-lean NAFLD [18]. However, these findings were criticized because baseline factors, especially cardiovascular disease (CVD) risk factors that might influence survival, are not evenly distributed between the lean and non-lean NAFLD. Thus, the pooled analysis only combined unadjusted risk estimates from studies, potentially leading to biased inferences about the exposure-outcome association. Furthermore, over the recent years, several large cohort studies in adults from the United States and Asia have examined the association between lean NAFLD and the risk of all-cause mortality [19–23]. Therefore, this systematic review and updated meta-analysis was conducted to comprehensively assess the association between a lean body mass and the long-term risk of all-cause mortality among patients with NAFLD by performing a pooled analysis of covariate-adjusted hazard ratios (HRs).

2Materials and Methods2.1Search methods for identification of studies

Two researchers independently performed a systematic review of the literature in the EMBASE and MEDLINE databases from inception to March 1st, 2023, to identify all longitudinal cohort studies that examined all-cause mortality of patients with lean NAFLD compared to populations with overweight or obese NAFLD. Supplementary Data 1 contains the search strategy outlining the search terms for “non-alcoholic fatty liver disease,” “lean,” “mortality,” and “survival”. To maximize the comprehensiveness of the systematic review, we searched and reviewed the references of included papers. However, the authors of potentially relevant articles were not contacted. The preferred reporting items for systematic reviews and meta-analyses (PRISMA) was used for this study protocol (Supplementary data 2). The study is registered on Open Science Framework, number osf.io/a9qfn.

2.2Study eligibility criteria

Studies were included in the meta-analysis if they met the following criteria: 1) longitudinal cohort studies comparing mortality between NAFLD patients with lean body mass and those with either non-lean, overweight, or obese body mass; 2) studies reporting adjusted HRs with 95 % confidence intervals (95 % CIs) values for the outcome of interest; and 3) studies diagnosing NAFLD with liver biopsy, imaging techniques, or surrogate indices. Both conference abstracts and full-text articles were eligible. Articles published in non-English languages were excluded. Lean or non-lean body mass was defined as BMI <23 or ≥23 kg/m2 for Asians and <25 or ≥25 kg/m2 for non-Asians, respectively. Overweight body mass was defined as BMI between 23 and 24.9 kg/m2 for Asians and BMI between 25 and 29.9 kg/m2 for non-Asians. Obese body mass was defined as BMI ≥25 kg/m2 for Asians and ≥30 kg/m2 for non-Asians. The first round of screening of titles and abstracts and the second round of full-text review were performed independently by two investigators (WW and NC) to ensure that the included studies met all eligible criteria. Any disagreements were resolved by consensus and, if necessary, a third author (PC).

2.3Data extraction and quality assessment

The following details were extracted using a standardized record form: the author, the year of publication, the country where the study was conducted, the study design, the number of participants, the identification and ascertainment of NAFLD participants, baseline characteristics of participants, including metabolic disorders of all patients, lean and non-lean patients, the average or median duration of follow-up, and covariates included in multivariable models. The primary outcome of interest was the comparative risk of all-cause mortality among individuals with lean NAFLD compared to non-lean NAFLD patients. A secondary outcome was to estimate the cause-specific mortality risks for patients with lean NAFLD. Covariate adjusted HR and 95 % CI for all-cause mortality in patients with lean-NAFLD versus those with non-lean NAFLD were recorded. Two researchers (WW and NC) utilized the Newcastle-Ottawa Scale (NOS) to evaluate the quality of the relevant cohort studies [24], and the senior investigator (PC) settled any disagreements.

2.4Statistical analysis and data synthesis

HRs were pooled via the inverse variance method using the DerSimonian and Laird random effects model to compare mortality between individuals with lean NAFLD and non-lean NAFLD patients [25]. The participants in the reference group were categorized into three groups based on whether they had non-lean, overweight, or obese NAFLD. Statistical heterogeneity was tested using the I2 test. An I2 ≥50 % or p <0.1 was suggestive of considerable heterogeneity among the studies [26].

To investigate potential sources of heterogeneity among the eligible studies and test the robustness of the observed associations, we stratified analyses according to methods for NAFLD diagnosis, study country, study setting (hospital-based vs. population-based studies), length of follow-up (<10 years vs. ≥10 years), NOS category (<8 stars vs. ≥8 stars), adjustment with fibrosis stage/cirrhosis, and a full adjustment for traditional CVD risk factors (defined as studies adjusting at least for age, sex, smoking history, type 2 diabetes mellitus, hypertension, and hyperlipidemia). We performed univariable meta-regression analyses to determine the impact of specific moderator variables (i.e., age, sex, smoking status, and percentage of type 2 diabetes mellitus, hypertension, and hyperlipidemia) on the effect size for adjusted HRs of all-cause mortality. We further conducted sensitivity analyses to test for the possible excessive influence of each study on overall results by excluding one study at a time. Finally, the possibility of publication bias was evaluated using the funnel plot and Egger's test if at least 10 studies were available. Review Manager 5.4 software from the Cochrane Collaboration (London, United Kingdom) was used for data analysis.

3Results3.1Characteristics of the included studies

A total of 2921 articles, including 2338 from EMBASE and 583 from MEDLINE, were retrieved. After 465 duplicated articles were found and eliminated, the remaining 2456 articles underwent the first-round review of titles and abstracts. A total of 2331 articles were removed because they didn't fulfill the eligibility criteria based on the study design and the outcome of interest. After the second round of reviews of 125 publications, 14 relevant observational studies with a total of 94,181 patients with NAFLD (11.3 % with lean NAFLD) were included in this meta-analysis. Eleven full-text articles [10-15,17,19-22] and three conference abstracts [9,16,23] explored the impact of lean body mass on all-cause mortality in the NAFLD population. One of the full-text articles, a study by Ito et al. [15], was a meta-analysis of individual patients from two cohorts in Japan [27,28]. These original cohort studies did not report the effect of lean body mass on our prerequisite outcomes. However, a study by Ito et al. re-analyzed original raw data and reported an HR of lean NAFLD on all-cause mortality [15]. Then, we included this study as a cohort study. Two studies examined the association between lean NAFLD and the risk of cause-specific mortality [12,20]. Fig. 1 provides an overview of the literature review and study selection process.

Fig. 1.

Flowchart of literature review and study selection.

(0.24MB).

Table 1 summarizes the study design, characteristics of participants, and the NOS of the included studies. The majority of these studies enrolled participants from general populations, national health examination surveys, or outpatient cohorts, in which NAFLD was diagnosed by liver biopsy, imaging techniques (mostly ultrasonography), or surrogate indices of fatty liver. Five studies were carried out in the United States; four studies were carried out in Asia (China, Japan, and Thailand); three studies were carried out in Europe (Austria, France, and Sweden); and two studies were international research collaborations. Eight studies received a score of nine stars on the NOS (studies at relatively low risk of bias), four studies received seven or eight stars (studies at medium risk of bias), and two studies received six stars (studies at high risk of bias). Patients with lean NAFLD in most included studies were more likely to have a lower prevalence of components of the metabolic syndrome, including type 2 diabetes mellitus, hypertension, and hyperlipidemia, than non-lean counterparts.

Table 1.

Characteristics of cohort studies assessing overall mortality between lean and non-lean NAFLD populations included in the review.

Author, year  Country  Number of lean NAFLD/non-lean NAFLD  Percentage of DM/DLP/HT in lean NAFLD  Percentage of DM/DLP/HT in non-lean NAFLD  Method of NAFLD diagnosis  Follow-up (year)  Adjusted confounders in multivariate analysis  Newcastle Ottawa Scores (Selection/ Comparability/Outcome) 
Ahmed, 2022 [10]  USA  414/4420  23.2/49.3/29.2  35.6/68.0/42.6  Ultrasound/ liver biopsy  6.4  age, sex, DM, HT, DLP  4/2/3 
Charatcharoenwitthaya, 2022 [19]  Thailand  1276/5807  28.8/72.1/53.4  34.9/57.8/61.9  Lipid accumulation product  8.5  age, sex, smoking, alcohol consumption, physical activity, DM, handgrip strength, Charlson comorbidity index  4/2/3 
Dela Cruz, 2014 [9]  Multicenter (USA, UK, Italy, Thailand, Australia)  75/697  15.5/27.6/20.4  28.5/38.1/30.9  Liver biopsy  11.1  age, sex, race, DM, HT, study site, and BMI  4/2/3 
Feldman, 2021 [11]  Austria  39/257  2.6/38.5/35.9  30.0/52.1/58.4  Liver biopsy  8.4  age, sex, fasting glucose, fibrosis stage  4/2/2 
Golabi, 2020 [12]  USA  797/2344  NA/NA/NA  NA/NA/NA  Ultrasound  22.4  age, sex, education, smoking, physical activity, DM, HT, DLP, FIB-4, previous cancer, previous CVD  4/2/3 
Hagstrom, 2018 [13]  Sweden  123/523  5.7/8.1/27.6  16.4/9.0/31.0  Liver biopsy  19.9  age, sex, DM, fibrosis stage  4/2/3 
Hirose, 2020 [14]  Japan  102/121  15.7/7.8/23.5  26.4/6.6/26.4  Liver biopsy  19.5  age, sex, alcohol consumption, DM, HT, DLP, pathologic findings  4/2/3 
Ito, 2021 [15]  Japan  983/3324  NA/NA/NA  NA/NA/NA  Ultrasound/ liver biopsy  7.1  age, sex, DM, Cr, FIB-4  4/2/3 
Lan, 2022 [20]  China  1543/21,654  14.3/NA/46.7  17.0/NA/60.4  Ultrasound  13.1  age, sex, education, smoking, alcohol consumption, physical activity, DM, HT, central obesity, triglycerides, low-density lipoprotein, high-density lipoprotein, C-reactive protein, and ALT  4/2/3 
Mansour, 2017 [16]  USA  68/1032  NA/NA/NA  NA/NA/NA  Ultrasound/ liver biopsy  NA  sex, cirrhosis  4/2/0 
Nabi, 2023 [21]  France  2563/22,040  10.5/25.1/30.6  17.9/32.3/31.6  Fatty liver index (>60)  3.8  age, sex, geographic origin, educational level, DM, HT, DLP, GGT, ALT, alcohol consumption, tobacco, soda, coffee, and physical exercise  4/2/2 
Nguyen, 2022 [23]  USA  978/8239 (9217)  NA/NA/NA  NA/NA/NA  Liver imaging  NA  age, sex, race and ethnicity, diabetes, cirrhosis, and non-liver cancer  4/2/0 
Wijarnpreecha, 2023 [22]  USA  1454/11,966 (13,420)  13.5/22.1/28.5  23.4/34.9/42.0  Ultrasound/ liver biopsy  4.1  age, sex, race, smoking, alcohol consumption, DM, HT, DLP, and use of aspirin or statin  4/2/1 
Younes, 2022 [17]  Multicenter (Australia, UK, Spain, Italy)  195/1144 (1339)  9.2/NA/NA  31.4/NA/NA  Liver biopsy  7.8  age, sex, BMI, DM, fibrosis stage, study site  4/2/2 

BMI, body mass index; Cr, creatinine; CVD, cardiovascular disease; DLP, dyslipidemia; DM, diabetes mellitus; FIB-4, fibrosis-4 index; FLI, fatty liver index; HT, hypertension; NA, Not available; NAFLD, non-alcoholic fatty liver; UK, the United Kingdom; USA, United States of America.

3.2Effect of lean body mass on overall and cause-specific mortalities among patients with NAFLD

Overall, these studies had aggregate data on 94,181 individuals with NAFLD (10,610 patients with lean NAFLD and 83,571 patients with non-lean NAFLD) and 7443 incident cases of fatal events over a median of mean/median follow-up of 8.4 years (interquartile range, 6.6–17.4 years). Patients with lean NAFLD were significantly associated with an increased risk of all-cause mortality compared to non-lean NAFLD patients with a pooled HR of 1.73 (95 % CI, 1.22–2.45; I2 = 81 %) [9,14-17,20,21], overweight NAFLD patients with a pooled HR of 1.44 (95 % CI, 1.09–1.90; I2 = 69 %) [11-13,22,23], obese NAFLD patients with a pooled HR of 1.65 (95 % CI, 1.25–2.17]; I2 = 81 %) [10-12,19,22,23], and their overall combined non-lean counterparts with a pooled HR of 1.61 (95 % CI, 1.37–1.89; I2 = 77 %) [9-17,19-23], as displayed in Fig. 2. Pooled estimates for all-cause mortality remained consistent in direction when the analysis was limited to the 11 full-text articles (pooled random-effects HR 1.51, 95 % CI, 1.26–1.81; test for overall effect Z = 4.42, P<0.0001; I2 = 79 %) [10-15,17,19-22].

Fig. 2.

Forest plots of pooled hazard ratios estimate all-cause mortality for lean NAFLD patients compared to those with non-lean NAFLD, overweight (Ow) NAFLD, and obese (Ob) NAFLD.

(0.55MB).

For cause-specific mortality, Golabi et al. showed that there was no significant difference in the risk of CVD-related mortality (a pooled HR 1.25, 95 % CI, 0.88–1.78; I2 = 45 %, Fig. 3A) and malignancy-related mortality (a pooled HR 1.20, 95 % CI, 0.94–1.52; I2 = 0 %, Fig. 3B) between patients with lean NAFLD and those with overweight or obese NAFLD [12]. On the other hand, Lan et al. found a significant association between patients with lean NAFLD and an increased risk of liver-related mortality, with an adjusted HR of 2.77 (95 % CI, 1.23–6.24), when compared to those with non-lean NAFLD [20].

Fig. 3.

Forest plots of pooled hazard ratios estimate (A) cardiovascular disease and (B) malignancy-related mortalities for lean NAFLD patients compared to those with overweight (Ow) and obese (Ob) NAFLD.

(0.34MB).
3.3Subgroup analyses, meta-regressions, and sensitivity analyses

We performed subgroup analyses to explore the possible sources of heterogeneity across the eligible studies (Table 2). The significant association between lean body mass and higher all-cause mortality risks in NAFLD subjects remained consistent across all the subgroups. In particular, the pooled random-effects HRs were comparable after stratification by the modality of NAFLD diagnosis, study country, types of cohort setting, length of follow-up, NOS quality scale, fibrosis stage/cirrhosis adjustment or degree of covariate adjustment.

Table 2.

Subgroup analyses for associations between lean NAFLD and risk of all-cause mortality.

  Random-effects Hazard Ratio (95 % CI)  Test for overall effect  Number of studies included  Number of subjects included  Heterogeneity I2,% 
NAFLD diagnosis
 Liver biopsy  1.58 (0.86–2.88)  Z = 1.49, P = 0.14  3279  73 % 
 Liver imaging  1.37 (1.11–1.70)  Z = 2.89, P = 0.004  35,555  67 % 
 Scoring systems  1.88 (0.75–4.68)  Z = 1.35, P = 0.18  31,686  96 % 
 Radiologic modalities/biopsy  1.86 (1.52–2.28)  Z = 5.98, P<0.0001  23,661  65 % 
Study country
 USA  1.66 (1.35–2.04)  Z = 4.77, P<0.0001  31,712  76 % 
 Asia  1.22 (0.94–1.59)  Z = 1.52, P = 0.13  34,810  71 % 
 Europe  2.34 (1.09–5.00)  Z = 2.19, P = 0.03  25,548  86 % 
 International  2.14 (1.44–3.16)  Z = 3.79, P = 0.0001  2111  0 % 
Study setting
 Hospital-based setting  1.79 (1.45–2.21)  Z = 5.46, P<0.0001  31,323  67 % 
 Population-based setting  1.41 (1.12–1.78)  Z = 2.89, P = 0.004  62,858  82 % 
Length of study follow-up*
 Follow-up <10 years  1.89 (1.49–2.39)  Z = 5.30, P<0.0001  55,885  77 % 
 Follow-up ≥10 years  1.21 (0.96–1.53)  Z = 1.61, P = 0.11  27,979  71 % 
NOS category
 NOS <8 stars  2.06 (1.80–2.34)  Z = 10.8, P<0.0001  23,737  8 % 
 NOS ≥8 stars  1.41 (1.16–1.72)  Z = 3.46, P = 0.0005  11  70,444  76 % 
Adjustment with fibrosis stage/cirrhosis
 No adjustment  1.58 (1.33–1.89)  Z = 5.07, P<0.0001  81,357  81 % 
 Adjustment  1.73 (1.14–2.63)  Z = 2.58, P = 0.010  12,824  70 % 
Degree of adjustment
 Minimal adjustment  1.66 (1.29–2.14)  Z = 3.92, P<0.0001  22,737  64 % 
 Maximal adjustment  1.58 (1.27–1.96)  Z = 4.09, P<0.0001  71,444  85 % 

NAFLD, non-alcoholic fatty liver disease; NOS, Newcastle-Ottawa Scale.

No data on the length of follow-up was reported in the two studies.

The diagnosis of NAFLD was established using either radiological modalities or liver biopsy in each of the individual studies.

Maximal covariate adjustment included studies that adjusted the results for fewer traditional cardiovascular disease risk factors: age, sex, smoking history, diabetes, hypertension, and dyslipidemia (or plasma lipid profile). Minimal covariate adjustment included all other eligible studies that have adjusted the results for a lower number of traditional cardiovascular disease risk factors than those listed above.

As shown in Fig. 4, the results of univariable meta-regression analyses to examine the effect of potential moderator variables showed a significant positive association between mean age and the risk of all-cause mortality (panel A). There were no significant effects of the proportion of male patients and smoking status, and the percentage of pre-existing type 2 diabetes mellitus, hypertension, and hyperlipidemia on the association between lean subjects and the risk of all-cause mortality in the population with NAFLD.

Fig. 4.

Meta-regression analyses to examine the effect of potential moderator variables on the association between lean NAFLD and the risk of all-cause mortality.

(0.34MB).

In sensitivity analyses, we found that the increased risk of all-cause mortality in lean NAFLD remained statistically significant when each study was removed from analysis at a time with the range of pooled HRs from 1.52 to 1.76, indicating no significant effect of any individual study on the overall risk of all-cause mortality (Table 3).

Table 3.

Sensitivity analyses for the association between lean NAFLD and risk of all-cause mortality.

  Random-effects Hazard Ratio (95 % CI)  Test for overall effect  HeterogeneityI2,% 
Dela Cruz, 2014 [9]  1.59 (1.35, 1.87)  Z = 5.47, P < 0.0001  78 % 
Mansour, 2017 [16]  1.58 (1.34, 1.86)  Z = 5.53, P < 0.0001  77 % 
Hagström, 2018 [13]  1.65 (1.40, 1.95)  Z = 6.00, P < 0.0001  77 % 
Hirose, 2020 [14]  1.66 (1.42, 1.94)  Z = 6.33, P < 0.0001  76 % 
Golabi, 2020 [12]  1.76 (1.49, 2.08)  Z = 6.59, P < 0.0001  75 % 
Ito, 2021 [15]  1.64 (1.39, 1.94)  Z = 5.80, P < 0.0001  78 % 
Feldman, 2021 [11]  1.57 (1.34, 1.85)  Z = 5.53, P < 0.0001  78 % 
Younes, 2022 [17]  1.61 (1.37, 1.89)  Z = 5.77, P < 0.0001  78 % 
Ahmed, 2022 [10]  1.61 (1.36, 1.91)  Z = 5.46, P < 0.0001  78 % 
Charatcharoenwitthaya, 2022 [19]  1.65 (1.39, 1.95)  Z = 5.87, P < 0.0001  76 % 
Lan, 2022 [20]  1.62 (1.35, 1.95)  Z = 5.16, P < 0.0001  78 % 
Nguyen, 2022 [23]  1.58 (1.33, 1.88)  Z = 5.16, P < 0.0001  79 % 
Nabi, 2023 [21]  1.55 (1.33, 1.80)  Z = 5.61, P < 0.0001  73 % 
Wijarnpreecha, 2023 [22]  1.52 (1.27, 1.82)  Z = 4.58, P < 0.0001  75 % 
3.4Risk of publication bias

As shown in Supplementary Figure 1, visual inspection of funnel plot and Egger's test did not show evidence of publication bias in the overall analysis for the association between lean NAFLD and risk of all-cause mortality (P = 0.682).

4Discussion

This updated meta-analysis of 14 observational studies reporting adjusted HRs (involving a total of 94,181 patients with NAFLD from different countries with 7443 incident cases of fatal events over a median follow-up of 8.4 years) revealed that lean NAFLD was associated with a ∼1.6-fold increased long-term risk of all-cause mortality (a pooled random-effects HR of 1.61, 95 % CI 1.37 to 1.89; test for overall effect Z = 5.84, P<0.0001; I2 = 77 %). The magnitude of this risk remained significant in those studies where analyses were adjusted for age, sex, smoking, and common cardiometabolic risk factors.

The findings of our meta-analysis with pooled estimates from adjusted HRs revealed significantly higher mortality in patients with lean NAFLD than those with non-lean NAFLD. These results differed from a previous meta-analysis of a pooled unadjusted relative risk (RR), which found a comparable risk of death between lean NAFLD and non-lean NAFLD (RR 1.09, 95 % CI 0.67–1.77; I2 = 97.7 %) [18]. The pooled HR is more relevant than the pooled RR when incorporating summary time-to-event data into meta-analysis. Because HR considers the number and timing of events and the time until the last follow-up for each patient who has not experienced an event, whereas RR only considers the number of events and disregards the timing [29]. The use of such dichotomous measures in a previous meta-analysis of time-to-event outcomes can lead some biases. When the total number of events reported for each cohort study with variable follow-up is used to calculate and combine RRs, this risk estimate is unreliable and difficult to interpret. Therefore, four cohort studies previously included in a meta-analysis by Ha et al. were excluded from our updated meta-analysis because they did not provide statistical information to estimate the HR [7,30-32]. Of note, our systematic review included five additional full-text articles [15,19-22] and three conference abstracts [9,16,23] of large cohort studies from China, Japan, Thailand, and the United States with an additional 83,699 NAFLD patients in quantitative analysis. In these studies, adjusted HRs were performed using the multivariate Cox models accounting for known risk factors for disease progression and the severity of liver fibrosis to determine the impact of lean body mass on mortality risk throughout follow-up. Therefore, our meta-analysis was more comprehensive regarding the number of eligible studies and the magnitude of a risk assessment.

The mechanisms underlying the increased mortality risk among patients with lean NAFLD remain unknown. Some evidence suggests that patients with lean NAFLD may face an elevated risk of clinically significant liver-related outcomes. A retrospective cohort study of patients with biopsy-proven NAFLD in Sweden revealed that patients with lean NAFLD are at a higher risk of developing cirrhosis, decompensated liver disease, or HCC, resulting in a higher incidence of liver-related death than their non-lean counterparts, despite having a lower prevalence of advanced fibrosis and steatohepatitis at baseline [13]. Consistent results were reported in a large community-based Chinese cohort study conducted by Lan et al., unveiling the significant association between lean NAFLD and an increased risk of liver-related mortality [20]. These observed differences in liver outcomes between lean and non-lean NAFLD patients could be attributed to differences in the genotype distribution of the patatin-like phospholipase domain-containing 3 (PNPLA3) gene among both groups. Lean NAFLD individuals are more likely to have the PNPLA3 GG genotype [33,34], which has been shown to modify the risk of NAFLD progression [35]. Furthermore, a nationwide population study in the United States reveals that the PNPLA3 rs738409 G variant is associated with increased liver-related mortality compared to the C allele [36]. Nonetheless, a retrospective cohort study from the University of Michigan Health System demonstrates that the PNPLA3 GG genotype is associated with a higher incidence of liver cirrhosis, but not all-cause mortality or non-liver outcomes, in both obese and non-obese individuals with NAFLD [22]. Further research is needed to better understand the underlying mechanisms and potential genetic factors contributing to the increased mortality risk in this patient population.

Many studies have highlighted favorable cardiometabolic profiles in individuals with lean NAFLD compared to those with non-lean NAFLD. A recent meta-analysis of 85 studies revealed that patients with lean NAFLD exhibited less metabolic dysfunction, including a lower prevalence of diabetes, lower fasting blood glucose levels, waist circumference, and blood pressure when compared to overweight or obese patients with NAFLD [37]. Our study aligns with previous reports, as we observed that lean NAFLD patients at the time of diagnosis had significantly lower rates of diabetes, dyslipidemia, and hypertension compared to their non-lean counterparts (Table 1) [9-11,13,14,17,19-22]. Since patients with lean NAFLD usually present with fewer metabolic comorbidities, it has been commonly believed that they would have a lower risk of developing CVD compared to those with higher BMI. However, a prospective cohort study of patients with NAFLD from the United States demonstrated that individuals without obesity are at a similar risk of developing metabolic disease and CVD during long-term follow-up as those with obesity [38]. This association is further supported by the longitudinal data of the general U.S. population reported by Golabi et al., showing comparable risk of CVD-related mortality between patients with lean NAFLD and non-lean NAFLD (Fig. 3A) [12]. Together, these findings suggest that although patients with lean NAFLD have a healthier cardiometabolic profile at baseline, the risk of developing CVD-related morbidity and mortality during follow-up is similar between patients with lean NAFLD and non-lean NAFLD. However, a causal relationship between lean NAFLD and cardiovascular outcomes needs to be confirmed through further prospective studies.

Our meta-analysis has several important strengths. We provide the most comprehensive and updated assessment of the prognostic relevance of lean body mass on the long-term risk of all-cause mortality among NAFLD patients. The data was incorporated from large cohort studies from Asia, Europe, and the United States. It is likely to accurately represent patients with NAFLD seen in clinical practice. Notably, the higher mortality risks associated with lean NAFLD were consistently observed across all subgroup analyses (such as references of non-lean, overweight, or obese subjects, modalities of NAFLD diagnosis, study country, cohort setting, length of follow-up, NOS quality scale, adjustment with fibrosis stage/cirrhosis, and degree of adjustment for potential confounders) and sensitivity analysis, supporting consistent effect of lean NAFLD and robustness of this evidence. Furthermore, since the results from three eligible studies were published as conference abstracts, the risk estimates for mortality risk may be inaccurate. However, when the pooled analyses were limited to 11 full-text articles, the direction of the association between lean NAFLD and mortality risk remained unchanged, suggesting a consistent effect of the disease. Finally, we believe that our comprehensive search did not miss any published reports, and visual inspection of the funnel plot and a formal statistical test revealed no evidence of any publication bias.

Our meta-analysis had some limitations. First, although we used a random-effects model, the results of this meta-analysis should be interpreted with caution, similar to a previously published meta-analysis [18], given the relatively high heterogeneity observed in a pooled analysis (I2 = 77 %, Fig. 2). We explored potential sources of statistical heterogeneity using stratified analyses, meta-regressions, and sensitivity analyses. This high heterogeneity could be attributed to differences in the demographic characteristics of study populations, the length of study follow-up, and methods used for NAFLD diagnosis. Our meta-regression analyses also showed that the association between lean NAFLD and all-cause mortality was modified by the mean age of the study population, suggesting an impact of the onset of lean NAFLD on adverse outcomes. Second, the majority of the eligible studies adjusted the outcome of interest for age, sex, type 2 diabetes, hypertension, hyperlipidemia, and other traditional CVD risk factors; however, the possibility of residual confounding by some unmeasured factors cannot be completely ruled out.

5Conclusions

This comprehensive systematic review and updated meta-analysis provides evidence for a significant association between lean body mass and the long-term risk of all-cause mortality in the NAFLD population. Due to the lower prevalence of metabolic comorbidities in patients with lean NAFLD, the management of lean NAFLD may need to differ from conventional lifestyle modifications focused on weight loss and metabolic control. Further studies exploring potential explanations for these findings would be essential to guide the management of lean NAFLD and eventually impact patient outcomes.

Author contributions

Wasit Wongtrakul and Natthinee Charatcharoenwitthaya: Conceptualization, Data curation, Investigation, Methodology, Resources, Software, Validation, Visualization, Writing – original draft, Writing – review & editing. Phunchai Charatcharoenwitthaya: Conceptualization, Data curation, Formal analysis, Funding acquisition, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

References
[1]
N. Stefan, H.U. Häring, K. Cusi.
Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies.
Lancet Diabetes Endocrinol, 7 (2019), pp. 313-324
[2]
Z.M. Younossi, A.B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, M. Wymer.
Global epidemiology of non-alcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.
Hepatology, 64 (2016), pp. 73-84
[3]
N. Chalasani, Z. Younossi, J.E. Lavine, A.M. Diehl, E.M. Brunt, K. Cusi, et al.
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.
Hepatology, 55 (2012), pp. 2005-2023
[4]
P. Angulo, D.E. Kleiner, S. Dam-Larsen, L.A. Adams, E.S. Bjornsson, P. Charatcharoenwitthaya, et al.
Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Non-alcoholic Fatty Liver Disease.
Gastroenterology, 149 (2015), pp. 389-397
[5]
T.G. Simon, B. Roelstraete, H. Khalili, H. Hagstrom, J.F. Ludvigsson.
Mortality in biopsy-confirmed non-alcoholic fatty liver disease: results from a nationwide cohort.
[6]
Q. Ye, B. Zou, Y.H. Yeo, J. Li, D.Q. Huang, Y. Wu, et al.
Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Lancet Gastroenterol Hepatol, 5 (2020), pp. 739-752
[7]
J.C.F. Leung, T.C.W. Loong, J.L. Wei, G.L.H. Wong, A.W.H. Chan, P.C.L. Choi, et al.
Histological severity and clinical outcomes of non-alcoholic fatty liver disease in nonobese patients.
Hepatology, 65 (2017), pp. 54-64
[8]
E. Weinberg, H.N. Trinh, R.J. Firpi, K.R. Bhamidimarri, S. Klein, L. Malahias, et al.
THU-345-Lean NAFLD patients have lower prevalence of cardiovascular, metabolic and severe liver disease compared to overweight or obese patients with NAFLD.
[9]
Dela Cruz A.C., Bugianesi E., George J., Day C.P., Liaquat H., Charatcharoenwitthaya P., et al. Characteristics and long-term prognosis of lean patients with non-alcoholic fatty liver disease. Gastroenterology 2014;146(5):S–909. https://doi.org/10.1016/S0016-5085(14)63307-2.
[10]
O.T. Ahmed, T. Gidener, K.C. Mara, J.J. Larson, T.M. Therneau, A.M. Allen.
Natural History of Non-alcoholic Fatty Liver Disease With Normal Body Mass Index: a Population-Based Study.
Clin Gastroenterol Hepatol, 20 (2022), pp. 1374-1381
[11]
A. Feldman, B. Wernly, G. Strebinger, S.K. Eder, S. Zandanell, D. Niederseer, et al.
Liver-related mortality is increased in lean subjects with non- alcoholic fatty liver disease compared to overweight and obese subjects.
J Gastrointestin Liver Dis, 30 (2021), pp. 366-373
[12]
P. Golabi, J.M. Paik, T. Arshad, Y. Younossi, A. Mishra, Z.M. Younossi.
Mortality of NAFLD according to the body composition and presence of metabolic abnormalities.
Hepatol Commun, 4 (2020), pp. 1136-1148
[13]
H. Hagström, P. Nasr, M. Ekstedt, U. Hammar, P. Stål, R. Hultcrantz, et al.
Risk for development of severe liver disease in lean patients with non-alcoholic fatty liver disease: a long-term follow-up study.
Hepatol Commun, 2 (2018), pp. 48-57
[14]
S. Hirose, K. Matsumoto, M. Tatemichi, K. Tsuruya, K. Anzai, Y. Arase, et al.
Nineteen-year prognosis in Japanese patients with biopsy-proven non-alcoholic fatty liver disease: lean versus overweight patients.
[15]
T. Ito, M. Ishigami, B. Zou, T. Tanaka, H. Takahashi, M. Kurosaki, et al.
The epidemiology of NAFLD and lean NAFLD in Japan: a meta-analysis with individual and forecasting analysis, 1995-2040.
Hepatol Int, 15 (2021), pp. 366-379
[16]
W. Mansour, S. Young, N.A. Hoppmann, A.K. Singal.
Lean patients with non-alcoholic fatty liver disease have worse survival rates, higher frequency of cirrhosis, and decompensation compared to non-lean patients.
[17]
R. Younes, O. Govaere, S. Petta, L. Miele, D. Tiniakos, A. Burt, et al.
Caucasian lean subjects with non-alcoholic fatty liver disease share long-term prognosis of non-lean: time for reappraisal of BMI-driven approach?.
[18]
J. Ha, S.Y. Yim, R. Karagozian.
Mortality and liver-related events in lean versus non-lean non-alcoholic fatty liver disease: a systematic review and meta-analysis.
Clin Gastroenterol Hepatol, (2022), pp. S1542-S3565
[19]
P. Charatcharoenwitthaya, K. Karaketklang, W. Aekplakorn.
Muscle strength, but not body mass index, is associated with mortality in patients with non-alcoholic fatty liver disease.
J Cachexia Sarcopenia Muscle, 13 (2022), pp. 2393-2404
[20]
Y. Lan, Y. Lu, J. Li, S. Hu, S. Chen, Y. Wang, et al.
Outcomes of subjects who are lean, overweight or obese with non-alcoholic fatty liver disease: a cohort study in China.
Hepatol Commun, 6 (2022), pp. 3393-3405
[21]
O. Nabi, N. Lapidus, J. Boursier, V. de Ledinghen, J.M. Petit, S. Kab, et al.
Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study).
Hepatology, 78 (2023), pp. 272-283
[22]
K. Wijarnpreecha, F. Li, S.K. Lundin, D. Suresh, M.W. Song, C. Tao, et al.
Higher mortality among lean patients with non-alcoholic fatty liver disease despite fewer metabolic comorbidities.
Aliment Pharmacol Ther, 57 (2023), pp. 1014-1027
[23]
V. Nguyen, A. Ha, J. Park, N. Rouillard, R. Le, A. Fong, et al.
Cirrhosis incidence and long-term mortality rate among lean, overweight, and obese patients with non-alcoholic fatty liver disease (NAFLD) in the United States.
Hepatology, (2022), pp. S742
[24]
Wells G.A., Shea B., O'Connell D., Peterson J., Welch V., Losos M., et al. The Newcastle–Ottawa scale (NOS) for assessing the quality of non-randomized studies in meta-analysis. 2000.
[25]
R. DerSimonian, N. Laird.
Meta-analysis in clinical trials.
Control Clin Trials, 7 (1986), pp. 177-188
[26]
J.P. Higgins, S.G. Thompson, J.J. Deeks, D.G. Altman.
Measuring inconsistency in meta-analyses.
[27]
T. Tada, T. Kumada, H. Toyoda, K. Mizuno, Y. Sone, T. Akita, et al.
Progression of liver fibrosis is associated with non-liver-related mortality in patients with non-alcoholic fatty liver disease.
Hepatol Commun, 1 (2017), pp. 899-910
[28]
T. Ito, M. Ishigami, Y. Ishizu, T. Kuzuya, T. Honda, K. Hayashi, et al.
Utility and limitations of noninvasive fibrosis markers for predicting prognosis in biopsy-proven Japanese non-alcoholic fatty liver disease patients.
J Gastroenterol Hepatol, 34 (2019), pp. 207-214
[29]
D.G. Altman, J.M. Bland.
Time to event (survival) data.
BMJ (Clinical research ed), 317 (1998), pp. 468-469
[30]
G. Semmler, S. Wernly, S. Bachmayer, I. Leitner, B. Wernly, M. Egger, et al.
Metabolic dysfunction-associated fatty liver disease (MAFLD)-rather a bystander than a driver of mortality.
J Clin Endocrinol Metab, 106 (2021), pp. 2670-2677
[31]
Y. Chang, Y.K. Cho, J. Cho, H.S. Jung, K.E. Yun, J. Ahn, et al.
Alcoholic and non-alcoholic fatty liver disease and liver-related mortality: a cohort study.
Am J Gastroenterol, 114 (2019), pp. 620-629
[32]
B. Zou, Y.H. Yeo, V.H. Nguyen, R. Cheung, E. Ingelsson, M.H. Nguyen.
Prevalence, characteristics and mortality outcomes of obese, nonobese and lean NAFLD in the United States, 1999-2016.
J Intern Med, 288 (2020), pp. 139-151
[33]
H. Lin, G.L. Wong, C. Whatling, A.W. Chan, H.H. Leung, C.H. Tse, et al.
Association of genetic variations with NAFLD in lean individuals.
Liver Int, 42 (2022), pp. 149-160
[34]
Z.Y. Zou, V.W. Wong, J.G. Fan.
Epidemiology of non-alcoholic fatty liver disease in non-obese populations: meta-analytic assessment of its prevalence, genetic, metabolic, and histological profiles.
J Dig Dis, 21 (2020), pp. 372-384
[35]
X.C. Dong.
PNPLA3-a potential therapeutic target for personalized treatment of chronic liver disease.
Front Med (Lausanne), 6 (2019), pp. 304
[36]
K. Wijarnpreecha, M. Scribani, P. Raymond, D.M. Harnois, A.P. Keaveny, A. Ahmed, et al.
PNPLA3 gene polymorphism and liver- and extrahepatic cancer-related mortality in the United States.
Clin Gastroenterol Hepatol, 19 (2021), pp. 1064-1066
[37]
A. Tang, C.H. Ng, P.H. Phang, K.E. Chan, Y.H. Chin, C.E. Fu, et al.
Comparative burden of metabolic dysfunction in lean NAFLD vs non-lean NAFLD - a systematic review and meta-analysis.
Clin Gastroenterol Hepatol, (2022),
[38]
A. Arvind, J.B. Henson, S.A. Osganian, C. Nath, L.M. Steinhagen, Z.N. Memel, et al.
Risk of cardiovascular disease in individuals with nonobese non-alcoholic fatty liver disease.
Hepatol Commun, 6 (2022), pp. 309-319
Copyright © 2024. Fundación Clínica Médica Sur, A.C.
Descargar PDF
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos